vs
Side-by-side financial comparison of CytomX Therapeutics, Inc. (CTMX) and NorthEast Community Bancorp, Inc. (NECB). Click either name above to swap in a different company.
NorthEast Community Bancorp, Inc. is the larger business by last-quarter revenue ($26.4M vs $18.7M, roughly 1.4× CytomX Therapeutics, Inc.). NorthEast Community Bancorp, Inc. runs the higher net margin — 40.9% vs -0.8%, a 41.7% gap on every dollar of revenue. On growth, NorthEast Community Bancorp, Inc. posted the faster year-over-year revenue change (3.9% vs -25.7%). NorthEast Community Bancorp, Inc. produced more free cash flow last quarter ($50.8M vs $-15.8M). Over the past eight quarters, NorthEast Community Bancorp, Inc.'s revenue compounded faster (1.8% CAGR vs -15.9%).
CytomX Therapeutics is a clinical-stage biotechnology company specializing in innovative cancer immunotherapies. It leverages its proprietary Probody technology platform to develop targeted therapies that activate exclusively in tumor microenvironments, minimizing off-target toxicities, with a pipeline covering multiple solid tumor indications and partnerships with leading global pharmaceutical firms.
NorthEast Community Bancorp, Inc. (MD) is a U.S.-based bank holding company operating primarily in the Mid-Atlantic region. It provides a comprehensive suite of consumer and commercial banking services, including deposit products, mortgage loans, small business financing, and wealth management solutions to individual and local enterprise clients.
CTMX vs NECB — Head-to-Head
Income Statement — Q2 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $18.7M | $26.4M |
| Net Profit | $-154.0K | $10.8M |
| Gross Margin | — | — |
| Operating Margin | -6.9% | 59.0% |
| Net Margin | -0.8% | 40.9% |
| Revenue YoY | -25.7% | 3.9% |
| Net Profit YoY | 97.6% | 5.8% |
| EPS (diluted) | — | $0.78 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $26.4M | ||
| Q3 25 | — | $27.0M | ||
| Q2 25 | $18.7M | $25.9M | ||
| Q1 25 | $50.9M | $25.5M | ||
| Q4 24 | $38.1M | $25.4M | ||
| Q3 24 | $33.4M | $27.6M | ||
| Q2 24 | $25.1M | $27.0M | ||
| Q1 24 | $41.5M | $25.5M |
| Q4 25 | — | $10.8M | ||
| Q3 25 | — | $11.9M | ||
| Q2 25 | $-154.0K | $11.2M | ||
| Q1 25 | $23.5M | $10.6M | ||
| Q4 24 | $18.9M | $10.2M | ||
| Q3 24 | $5.7M | $12.7M | ||
| Q2 24 | $-6.5M | $12.8M | ||
| Q1 24 | $13.8M | $11.4M |
| Q4 25 | — | 59.0% | ||
| Q3 25 | — | 61.6% | ||
| Q2 25 | -6.9% | 59.5% | ||
| Q1 25 | 44.4% | 57.4% | ||
| Q4 24 | 46.4% | 57.0% | ||
| Q3 24 | 12.3% | 63.6% | ||
| Q2 24 | -33.7% | 65.6% | ||
| Q1 24 | 28.1% | 62.7% |
| Q4 25 | — | 40.9% | ||
| Q3 25 | — | 44.0% | ||
| Q2 25 | -0.8% | 43.1% | ||
| Q1 25 | 46.2% | 41.4% | ||
| Q4 24 | 49.6% | 40.1% | ||
| Q3 24 | 17.2% | 45.9% | ||
| Q2 24 | -26.0% | 47.5% | ||
| Q1 24 | 33.3% | 44.5% |
| Q4 25 | — | $0.78 | ||
| Q3 25 | — | $0.87 | ||
| Q2 25 | — | $0.82 | ||
| Q1 25 | — | $0.78 | ||
| Q4 24 | — | $0.74 | ||
| Q3 24 | — | $0.95 | ||
| Q2 24 | — | $0.97 | ||
| Q1 24 | — | $0.86 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $49.0M | $81.2M |
| Total DebtLower is stronger | — | $70.0M |
| Stockholders' EquityBook value | $119.9M | $351.7M |
| Total Assets | $175.1M | $2.1B |
| Debt / EquityLower = less leverage | — | 0.20× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $81.2M | ||
| Q3 25 | — | $64.3M | ||
| Q2 25 | $49.0M | $59.4M | ||
| Q1 25 | $47.6M | $89.5M | ||
| Q4 24 | $38.1M | $78.3M | ||
| Q3 24 | $40.6M | $97.8M | ||
| Q2 24 | $43.2M | $113.9M | ||
| Q1 24 | $36.2M | $107.4M |
| Q4 25 | — | $70.0M | ||
| Q3 25 | — | $170.0M | ||
| Q2 25 | — | $135.0M | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | $7.0M | ||
| Q2 24 | — | $47.0M | ||
| Q1 24 | — | $47.0M |
| Q4 25 | — | $351.7M | ||
| Q3 25 | — | $344.0M | ||
| Q2 25 | $119.9M | $336.7M | ||
| Q1 25 | $25.0M | $327.2M | ||
| Q4 24 | $-456.0K | $318.3M | ||
| Q3 24 | $-23.5M | $309.6M | ||
| Q2 24 | $-31.2M | $300.0M | ||
| Q1 24 | $-31.7M | $288.9M |
| Q4 25 | — | $2.1B | ||
| Q3 25 | — | $2.1B | ||
| Q2 25 | $175.1M | $2.0B | ||
| Q1 25 | $98.5M | $1.9B | ||
| Q4 24 | $120.5M | $2.0B | ||
| Q3 24 | $139.0M | $2.0B | ||
| Q2 24 | $159.2M | $1.9B | ||
| Q1 24 | $184.7M | $1.9B |
| Q4 25 | — | 0.20× | ||
| Q3 25 | — | 0.49× | ||
| Q2 25 | — | 0.40× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 0.02× | ||
| Q2 24 | — | 0.16× | ||
| Q1 24 | — | 0.16× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-15.8M | $52.6M |
| Free Cash FlowOCF − Capex | $-15.8M | $50.8M |
| FCF MarginFCF / Revenue | -84.6% | 192.3% |
| Capex IntensityCapex / Revenue | 0.1% | 6.6% |
| Cash ConversionOCF / Net Profit | — | 4.86× |
| TTM Free Cash FlowTrailing 4 quarters | $-77.7M | $89.9M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $52.6M | ||
| Q3 25 | — | $14.1M | ||
| Q2 25 | $-15.8M | $15.6M | ||
| Q1 25 | $-21.0M | $10.9M | ||
| Q4 24 | $-19.9M | $48.7M | ||
| Q3 24 | $-20.7M | $14.4M | ||
| Q2 24 | $-19.5M | $11.1M | ||
| Q1 24 | $-26.0M | $12.9M |
| Q4 25 | — | $50.8M | ||
| Q3 25 | — | $13.6M | ||
| Q2 25 | $-15.8M | $14.9M | ||
| Q1 25 | $-21.2M | $10.6M | ||
| Q4 24 | $-20.0M | $48.2M | ||
| Q3 24 | $-20.7M | $14.2M | ||
| Q2 24 | $-19.6M | $11.0M | ||
| Q1 24 | $-26.2M | $12.8M |
| Q4 25 | — | 192.3% | ||
| Q3 25 | — | 50.5% | ||
| Q2 25 | -84.6% | 57.3% | ||
| Q1 25 | -41.6% | 41.4% | ||
| Q4 24 | -52.5% | 189.3% | ||
| Q3 24 | -62.1% | 51.5% | ||
| Q2 24 | -78.2% | 40.8% | ||
| Q1 24 | -63.1% | 50.3% |
| Q4 25 | — | 6.6% | ||
| Q3 25 | — | 1.6% | ||
| Q2 25 | 0.1% | 2.9% | ||
| Q1 25 | 0.2% | 1.5% | ||
| Q4 24 | 0.2% | 2.0% | ||
| Q3 24 | 0.1% | 0.6% | ||
| Q2 24 | 0.4% | 0.5% | ||
| Q1 24 | 0.3% | 0.3% |
| Q4 25 | — | 4.86× | ||
| Q3 25 | — | 1.18× | ||
| Q2 25 | — | 1.40× | ||
| Q1 25 | -0.89× | 1.04× | ||
| Q4 24 | -1.05× | 4.77× | ||
| Q3 24 | -3.61× | 1.14× | ||
| Q2 24 | — | 0.87× | ||
| Q1 24 | -1.89× | 1.13× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CTMX
| Bristol Myers Squibb Company | $11.6M | 62% |
| Astellas Pharma Inc | $4.6M | 25% |
| Regeneron Pharmaceuticals Inc | $2.1M | 11% |
NECB
Segment breakdown not available.
